$74m market cap
$2.3 last close
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for chronic liver disease. The company’s lead asset is CRV431, a cyclophilin inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH).
Investment summary
Hepion has announced interim results from its ongoing Phase IIa study of CRV431 in non-alcoholic steatohepatitis (NASH). The preliminary results are from the low-dose arm of the study (75mg, n=12) and showed a 18.4% decline in alanine aminotransferase (ALT) and a 12.1% decline in aspartate aminotransferase (AST) liver biomarkers after 28 days. Although these data were underpowered for significance, this is the first indication of meaningful clinical activity in this patient group. This is the first look at the potential for this drug and, although small, it is very encouraging.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.0 | (14.3) | (9.8) | (5018.18) | N/A | N/A |
| 2019A | 0.0 | (7.7) | (7.9) | (326.09) | N/A | N/A |
| 2020E | 0.0 | (17.2) | (17.5) | (165.41) | N/A | N/A |
| 2021E | 0.0 | (18.5) | (18.5) | (57.93) | N/A | N/A |
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 42.6 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Robert Foster | CEO |
| John Cavan | FD |
